Ocular Therapeutix (NASDAQ: OCUL) reported Q3 EPS of ($0.25), $0.04 better than the analyst estimate of ($0.29). Revenue for the quarter came in at $15.08 million versus the consensus estimate of $15.23 million.

For earnings history and earnings-related data on Ocular Therapeutix (OCUL) click here.